ZMYND11

Summary

ZMYND11 (zinc finger MYND-type containing 11, HGNC:16966) is a protein-coding gene on chromosome 10p15.3, encoding Zinc finger MYND domain-containing protein 11 (Q15326). Chromatin reader that specifically recognizes and binds histone H3.3 trimethylated at ‘Lys-36’ (H3.3K36me3) and regulates RNA polymerase II elongation. It is haploinsufficient (ClinGen: sufficient evidence).

The protein encoded by this gene was first identified by its ability to bind the adenovirus E1A protein. The protein localizes to the nucleus. It functions as a transcriptional repressor, and expression of E1A inhibits this repression. Alternatively spliced transcript variants encoding different isoforms have been identified.

Source: NCBI Gene 10771 — RefSeq curated summary.

At a glance

• Gene–disease (curated): syndromic complex neurodevelopmental disorder (Definitive, ClinGen) — +2 more curated relationships
• GWAS associations: 2
• Clinical variants (ClinVar): 343 total — 41 pathogenic, 27 likely-pathogenic
• Phenotypes (HPO): 18
• Druggable target: yes
• Dosage sensitivity (ClinGen): haploinsufficiency sufficient evidence, triplosensitivity no evidence
• MANE Select transcript: NM_001370100

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16966
Approved symbol	ZMYND11
Name	zinc finger MYND-type containing 11
Location	10p15.3
Locus type	gene with protein product
Status	Approved
Aliases	BS69, BRAM1
Ensembl gene	ENSG00000015171
Ensembl biotype	protein_coding
OMIM	608668
Entrez	10771

Gene structure

Transcript identifiers

Ensembl transcripts: 87 — 80 protein_coding, 3 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined, 2 retained_intron

ENST00000381584, ENST00000381591, ENST00000381604, ENST00000397955, ENST00000397962, ENST00000402736, ENST00000403354, ENST00000439456, ENST00000473115, ENST00000488275, ENST00000509513, ENST00000558098, ENST00000602682, ENST00000627286, ENST00000704295, ENST00000704301, ENST00000704303, ENST00000704306, ENST00000704307, ENST00000704315, ENST00000704335, ENST00000704336, ENST00000704338, ENST00000704339, ENST00000704340, ENST00000704343, ENST00000857249, ENST00000857250, ENST00000857251, ENST00000857252, ENST00000857253, ENST00000857254, ENST00000857255, ENST00000857256, ENST00000857257, ENST00000857258, ENST00000857259, ENST00000857260, ENST00000857261, ENST00000857262, ENST00000857263, ENST00000857264, ENST00000857265, ENST00000857266, ENST00000857267, ENST00000857268, ENST00000857269, ENST00000857270, ENST00000857271, ENST00000857272, ENST00000857274, ENST00000857275, ENST00000857276, ENST00000857277, ENST00000857278, ENST00000857279, ENST00000857280, ENST00000857281, ENST00000857282, ENST00000857283, ENST00000857284, ENST00000917037, ENST00000917038, ENST00000917039, ENST00000917040, ENST00000917041, ENST00000972238, ENST00000972239, ENST00000972240, ENST00000972241, ENST00000972242, ENST00000972243, ENST00000972244, ENST00000972245, ENST00000972246, ENST00000972247, ENST00000972248, ENST00000972249, ENST00000972250, ENST00000972251, ENST00000972252, ENST00000972253, ENST00000972254, ENST00000972255, ENST00000972256, ENST00000972257, ENST00000972258

RefSeq mRNA: 36 — MANE Select: NM_001370100 NM_001202464, NM_001202465, NM_001202466, NM_001202467, NM_001202468, NM_001330057, NM_001370097, NM_001370098, NM_001370099, NM_001370100, NM_001370101, NM_001370102, NM_001370103, NM_001370104, NM_001370105, NM_001370106, NM_001370107, NM_001370108, NM_001370109, NM_001370110, NM_001370111, NM_001370112, NM_001370113, NM_001370114, NM_001370115, NM_001370116, NM_001370117, NM_001370118, NM_001370119, NM_001370120, NM_001370121, NM_001370122, NM_001370123, NM_001370124, NM_006624, NM_212479

CCDS: CCDS55696, CCDS55697, CCDS7052, CCDS7053, CCDS73060, CCDS91194, CCDS91195, CCDS91196, CCDS91197, CCDS91198, CCDS91199

Canonical transcript exons

ENST00000381604 — 15 exons

Exon	Start	End
ENSE00001489197	252348	254637
ENSE00001787371	248903	249088
ENSE00003261460	248336	248608
ENSE00003288785	221195	221356
ENSE00003361513	240056	240111
ENSE00003401615	239438	239525
ENSE00003538020	247398	247466
ENSE00003542361	240893	240970
ENSE00003547438	209889	210048
ENSE00003593216	246766	246973
ENSE00003595316	179994	180128
ENSE00003619373	236838	236915
ENSE00003627885	242021	242139
ENSE00003902290	135455	135559
ENSE00003991267	237585	237677

Expression profiles

Bgee: expression breadth ubiquitous, 301 present calls, max score 99.39.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 20.4183 / max 358.8404, expressed in 1774 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
103404	11.5260	1733
103401	2.6146	1357
103406	1.5356	934
103399	1.5317	630
103405	1.3835	887
205701	0.6740	394
103402	0.5487	312
103398	0.2966	111
103400	0.1494	45
103403	0.1199	41

Top tissues by expression

301 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cranial nerve II	UBERON:0000941	99.39	gold quality
caput epididymis	UBERON:0004358	99.38	gold quality
cauda epididymis	UBERON:0004360	99.31	gold quality
corpus epididymis	UBERON:0004359	99.17	gold quality
mammary duct	UBERON:0001765	99.15	gold quality
inferior vagus X ganglion	UBERON:0005363	98.89	gold quality
corpus callosum	UBERON:0002336	98.88	gold quality
superior vestibular nucleus	UBERON:0007227	98.87	gold quality
postcentral gyrus	UBERON:0002581	98.83	gold quality
Brodmann (1909) area 46	UBERON:0006483	98.83	gold quality
medulla oblongata	UBERON:0001896	98.82	gold quality
epithelium of mammary gland	UBERON:0003244	98.81	gold quality
parietal lobe	UBERON:0001872	98.78	gold quality
saphenous vein	UBERON:0007318	98.78	gold quality
subthalamic nucleus	UBERON:0001906	98.70	gold quality
superficial temporal artery	UBERON:0001614	98.69	gold quality
cardia of stomach	UBERON:0001162	98.68	gold quality
renal medulla	UBERON:0000362	98.60	gold quality
CA1 field of hippocampus	UBERON:0003881	98.54	gold quality
orbitofrontal cortex	UBERON:0004167	98.54	gold quality
ventral tegmental area	UBERON:0002691	98.53	gold quality
globus pallidus	UBERON:0001875	98.51	gold quality
visceral pleura	UBERON:0002401	98.51	gold quality
pons	UBERON:0000988	98.48	gold quality
trigeminal ganglion	UBERON:0001675	98.47	gold quality
lateral globus pallidus	UBERON:0002476	98.47	gold quality
pylorus	UBERON:0001166	98.46	gold quality
gluteal muscle	UBERON:0002000	98.46	gold quality
medial globus pallidus	UBERON:0002477	98.46	gold quality
dorsal plus ventral thalamus	UBERON:0001897	98.43	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.95
E-ENAD-17	no	221.23

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1 targets.

Target	Regulation
IL6	Activation

miRNA regulators (miRDB)

233 targeting ZMYND11, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-196A-5P	100.00	68.16	684
HSA-MIR-196B-5P	100.00	68.16	681
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-3065-5P	99.97	71.56	3281

Functional genomics

ClinGen dosage: haploinsufficiency 3 (sufficient evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 26)

• The adenovirus E1A binding protein BS69 is a corepressor of transcription through recruitment of N-CoR. (PMID:10734313)
• the C-terminal Mynd domain of BS69 (amino acids 516-561) or Mynd domains of the Caenorhabditis elegans proteins Bra-1 and Bra-2 bind not only to E1A but also to the Epstein-Barr virus EBNA2 oncoprotein and the Myc-related cellular protein MGA (PMID:11733528)
• BS69 controls E1A stability via inhibition of ubiquitination. (PMID:16300738)
• The recruitment and aggregation of BS69 is a prerequisite for JNK activation by LMP1. (PMID:16382137)
• BS69 has roles in gene repression and chromatin remodeling (PMID:16565076)
• Data indicate that BS69 is involved in cellular senescence mainly through the p53-p21Cip1 pathway. (PMID:17721438)
• BS69 forms oligomers. The PHD and MYND domains are important for the cellular localization of BS69. PIAS1 and Ubc9 interact with BS69 and promote the sumoylation of BS69. BS69 plays inhibitory roles in both muscle and neuron differentiation. (PMID:19766626)
• Knockdown of BS69 resulted in a decrease of IFN-beta induction, suggesting that BS69 is a positive regulator for the TLR3-TICAM-1 pathway and negative regulatory properties in NF-kappaB activation. (PMID:19795416)
• Data found that BS69 directly interacted with TRAF3, a negative regulator of NF-kappaB activation. Results revealed that TRAF3 was involved in the BS69-mediated suppression of LMP1/CTAR1-induced NF-kappaB activation. (PMID:20138174)
• Data show significant association between the copy number variations of BS69 and some hematological malignancies. (PMID:20425112)
• BRAM1 acts as a negative signal regulator located at the very proximal end of lymphotoxin beta receptor complex assembly. (PMID:20732415)
• identification of ZMYND11 as an H3.3-specific reader of H3K36me3 that links the histone-variant-mediated transcription elongation control to tumor suppression (PMID:24590075)
• We propose that BS69 specifically associates with H3K36me3-enriched chromatin through the PWWP domain, which facilitates the recruitment of MYND-bound transcription and chromatin remodeling factors (PMID:24675531)
• ZMYND11 represses gene expression by binding H3.3K36me3 and preventing transcription elongation. (PMID:24795016)
• this study identifies an H3.3K36me3-specific reader and a regulator of intron retention and reveals that BS69 connects histone H3.3K36me3 to regulated RNA splicing, providing significant, important insights into chromatin regulation of pre-mRNA processing. (PMID:25263594)
• In this study, we show that this translocation results in an in-frame translocation fusing exon 12 of the tumor suppressor gene ZMYND11 to exon 3 of the chromatin protein MBTD1, encoding a protein of 1,054 amino acids (PMID:26608508)
• Interaction with ZMYND11 mediates opposing roles of Ras-responsive ETS1 and ETS2. (PMID:28119415)
• The ZMYND11 gene has important functions in epigenetic regulation. (PMID:28933030)
• Taken together, ZMYND11 was demonstrated to be a potential and extremely promising suppressor of GBM, while miRNA-196a-5p was quite an important target of treatment of GBM. (PMID:29066350)
• the E1A proteins from HAdV-C5 and -A12 bind the cellular repressor protein BS69. This occurs via a SLiM containing a conserved PXLXP motif, which is present in CR2 of E1A. This SLiM confers interaction with the MYND domain of BS69. (PMID:30469473)
• Our data indicate that increased association with BS69 restricts the function of type 2 EBNA2 as a transcriptional activator and driver of B cell growth and may contribute to reduced B-cell transformation by type 2 EBV. (PMID:31283782)
• ZMYND11-related syndromic intellectual disability: 16 patients delineating and expanding the phenotypic spectrum. (PMID:32097528)
• MicroRNA-196b promotes cell growth and metastasis of ovarian cancer by targeting ZMYND11. (PMID:32512976)
• ZMYND11-MBTD1 induces leukemogenesis through hijacking NuA4/TIP60 acetyltransferase complex and a PWWP-mediated chromatin association mechanism. (PMID:33594072)
• ZMYND11 variants are a novel cause of centrotemporal and generalised epilepsies with neurodevelopmental disorder. (PMID:34216016)
• Oncogenic ZMYND11-MBTD1 fusion protein anchors the NuA4/TIP60 histone acetyltransferase complex to the coding region of active genes. (PMID:35705031)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	zmynd11	ENSDARG00000057249
mus_musculus	Zmynd11	ENSMUSG00000021156
rattus_norvegicus	Zmynd11	ENSRNOG00000014670
drosophila_melanogaster	CG8569	FBGN0033752

Paralogs (5): PHF21B (ENSG00000056487), ZMYND8 (ENSG00000101040), PHF12 (ENSG00000109118), PHF21A (ENSG00000135365), AIRE (ENSG00000160224)

Protein

Protein identifiers

Zinc finger MYND domain-containing protein 11 — Q15326 (reviewed: Q15326)

Alternative names: Adenovirus 5 E1A-binding protein, Bone morphogenetic protein receptor-associated molecule 1, Protein BS69

All UniProt accessions (15): Q15326, A0A0A0MRY2, A0A0D9SGD6, A0A994J4C0, A0A994J4I8, A0A994J4J2, A0A994J4Y4, A0A994J6Y5, A0A994J7D2, B0QZE2, B7Z2J6, E7ENI9, E7EV75, E9PE09, J3QKD2

UniProt curated annotations — full annotation on UniProt →

Function. Chromatin reader that specifically recognizes and binds histone H3.3 trimethylated at ‘Lys-36’ (H3.3K36me3) and regulates RNA polymerase II elongation. Does not bind other histone H3 subtypes (H3.1 or H3.2). Colocalizes with highly expressed genes and functions as a transcription corepressor by modulating RNA polymerase II at the elongation stage. Binds non-specifically to dsDNA. Acts as a tumor-suppressor by repressing a transcriptional program essential for tumor cell growth. (Microbial infection) Inhibits Epstein-Barr virus EBNA2-mediated transcriptional activation and host cell proliferation, through direct interaction.

Subunit / interactions. Homooligomer; forms homooligomers via its C-terminus. Interacts with histone H3.3 trimethylated at ‘Lys-36’ (H3.3K36me3). Interacts (via MYND-type zinc finger) with NCOR1. Interacts (via MYND-type zinc finger) with MGA protein (via PXLXP motif). Interacts (via MYND-type zinc finger) with EZH2. Interacts with EMSY and E2F6. Interacts with PIAS1 and UBE2I. (Microbial infection) Interacts (via MYND-type zinc finger) with human adenovirus early E1A protein (via PXLXP motif); this interaction inhibits E1A mediated transactivation. (Microbial infection) Interacts (via MYND-type zinc finger) with Epstein-Barr virus EBNA2 protein (via PXLXP motif). Interacts with Epstein-Barr virus-derived protein LMP1; leading to negatively regulate NF-kappa-B activation by Epstein-Barr virus-derived protein LMP1.

Subcellular location. Nucleus. Chromosome.

Tissue specificity. Ubiquitous.

Post-translational modifications. Sumoylated following its interaction with PIAS1 and UBE2I. Ubiquitinated, leading to proteasomal degradation.

Disease relevance. A chromosomal aberration involving ZMYND11 is a cause of acute poorly differentiated myeloid leukemia. Translocation (10;17)(p15;q21) with MBTD1. Intellectual developmental disorder, autosomal dominant 30, with speech delay and behavioral abnormalities (MRD30) [MIM:616083] A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD30 patients manifest intellectual disability, speech delay, and subtle facial dysmorphisms, including hypertelorism, ptosis, and a wide mouth. Behavioral abnormalities, including attention deficit-hyperactivity disorder, autistic features, and aggression are commonly observed. The disease is caused by variants affecting the gene represented in this entry.

Domain organisation. The PWWP domain specifically recognizes and binds histone H3.3 trimethylated at ‘Lys-36’ (H3.3K36me3) and adopts a five-bladed beta-barrel fold with an extended C-terminal alpha-helix, with a conserved H3.3K36me3-binding aromatic cage formed by Phe-291 and Trp-294 of the beta1-beta2 loop and Phe-310 of the beta3-beta4 loop. Specific recognition of H3.3 histone is mediated by the encapsulation of the H3.3-specific ‘Ser 31’ residue in a composite pocket formed by the tandem bromo-PWWP domains.

Induction. Down-regulated in breast cancer patients with poor prognosis.

Isoforms (6)

UniProt ID	Names	Canonical?
Q15326-1	1	yes
Q15326-2	2
Q15326-3	3
Q15326-4	4
Q15326-5	5
Q15326-6	6

RefSeq proteins (36): NP_001189393, NP_001189394, NP_001189395, NP_001189396, NP_001189397, NP_001316986, NP_001357026, NP_001357027, NP_001357028, NP_001357029, NP_001357030, NP_001357031, NP_001357032, NP_001357033, NP_001357034, NP_001357035, NP_001357036, NP_001357037, NP_001357038, NP_001357039, NP_001357040, NP_001357041, NP_001357042, NP_001357043, NP_001357044, NP_001357045, NP_001357046, NP_001357047, NP_001357048, NP_001357049, NP_001357050, NP_001357051, NP_001357052, NP_001357053, NP_006615, NP_997644 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000313	PWWP_dom	Domain
IPR001487	Bromodomain	Domain
IPR001965	Znf_PHD	Domain
IPR002893	Znf_MYND	Domain
IPR011011	Znf_FYVE_PHD	Homologous_superfamily
IPR013083	Znf_RING/FYVE/PHD	Homologous_superfamily
IPR019786	Zinc_finger_PHD-type_CS	Conserved_site
IPR019787	Znf_PHD-finger	Domain
IPR036427	Bromodomain-like_sf	Homologous_superfamily
IPR047268	PWWP_BS69	Domain
IPR047269	ZMY11	Family
IPR048589	SAMD1-like_WH	Domain
IPR057053	MYND_ZMYND11_ZMYD8	Domain
IPR057054	ZMYND11_CC	Domain

Pfam: PF00439, PF00855, PF21524, PF23461, PF24324

UniProt features (67 total): mutagenesis site 17, binding site 12, helix 12, strand 8, splice variant 4, domain 3, cross-link 3, zinc finger region 2, region of interest 2, chain 1, modified residue 1, short sequence motif 1, compositionally biased region 1

Structure

Experimental structures (PDB)

8 structures.

PDB	Method	Resolution (Å)
8XU6	X-RAY DIFFRACTION	1.63
9LOM	X-RAY DIFFRACTION	1.63
9LOA	X-RAY DIFFRACTION	1.8
9M0U	X-RAY DIFFRACTION	1.89
4NS5	X-RAY DIFFRACTION	1.9
5HDA	X-RAY DIFFRACTION	2.39
9LP4	X-RAY DIFFRACTION	2.96
9VC7	X-RAY DIFFRACTION	3.35

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q15326-F1	82.95	0.66

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (12): 258; 261; 277; 281; 563; 566; 574; 575; 581; 585; 594; 598

Post-translational modifications (4): 421, 366, 407, 408

Mutagenesis-validated functional residues (17):

Position	Phenotype
258–261	no effect on nuclear location.
287	abolishes binding to dna. no effect on nuclear location.
289	abolishes binding to dna. no effect on nuclear location.
291	no effect on nuclear location.
294	abolishes interaction with histone 3. diffused distribution in the nucleus.
310	diffused distribution in the nucleus.
334	decreases binding to dna.
338–339	no effect on interaction with histone 3. abolishes binding to dna. changes location from nuclear to cytoplasmic.
344–345	abolishes binding to dna. no effect on nuclear location.
562	reduced interaction with pxlxp ligand mga without affecting interaction with viral human adenovirus early e1a protein.
563	abrogates binding to ezh2.
567–568	reduced interaction with pxlxp ligand proteins.
572	decreases interaction with epstein-barr virus ebna2 protein.
586	highly decreases interaction with epstein-barr virus ebna2 protein. no effect on the inhibition of ebna2-mediated transc
590	highly decreases interaction with epstein-barr virus ebna2 protein. almost abolishes interaction with epstein-barr virus
599–602	abolished interaction with pxlxp ligand proteins.
600	highly decreases interaction with epstein-barr virus ebna2 protein.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 320 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_DN, BORCZUK_MALIGNANT_MESOTHELIOMA_UP, AAGCAAT_MIR137, ACTACCT_MIR196A_MIR196B, FAELT_B_CLL_WITH_VH_REARRANGEMENTS_DN, BASSO_B_LYMPHOCYTE_NETWORK, GOBP_CANONICAL_NF_KAPPAB_SIGNAL_TRANSDUCTION, GOBP_EXTRINSIC_APOPTOTIC_SIGNALING_PATHWAY, CACCAGC_MIR138, CHANDRAN_METASTASIS_DN, GOBP_NEGATIVE_REGULATION_OF_MAPK_CASCADE, GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, GOBP_NEGATIVE_REGULATION_OF_EXTRINSIC_APOPTOTIC_SIGNALING_PATHWAY, MARTINEZ_RB1_TARGETS_UP, CAGCAGG_MIR370

GO Biological Process (8): regulation of signal transduction (GO:0009966), regulation of transcription elongation by RNA polymerase II (GO:0034243), negative regulation of canonical NF-kappaB signal transduction (GO:0043124), negative regulation of DNA-templated transcription (GO:0045892), negative regulation of JNK cascade (GO:0046329), defense response to virus (GO:0051607), negative regulation of extrinsic apoptotic signaling pathway (GO:2001237), chromatin organization (GO:0006325)

GO Molecular Function (7): double-stranded DNA binding (GO:0003690), transcription corepressor activity (GO:0003714), zinc ion binding (GO:0008270), histone H3K36me3 reader activity (GO:0140003), DNA binding (GO:0003677), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (4): nucleus (GO:0005634), nucleoplasm (GO:0005654), chromosome (GO:0005694), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
signal transduction	1
regulation of cell communication	1
regulation of signaling	1
regulation of response to stimulus	1
transcription elongation by RNA polymerase II	1
regulation of DNA-templated transcription elongation	1
canonical NF-kappaB signal transduction	1
regulation of canonical NF-kappaB signal transduction	1
negative regulation of intracellular signal transduction	1
DNA-templated transcription	1
regulation of DNA-templated transcription	1
negative regulation of RNA biosynthetic process	1
JNK cascade	1
negative regulation of MAPK cascade	1
regulation of JNK cascade	1
defense response	1
response to virus	1
extrinsic apoptotic signaling pathway	1
negative regulation of apoptotic signaling pathway	1
regulation of extrinsic apoptotic signaling pathway	1
cellular component organization	1
DNA binding	1
transcription coregulator activity	1
negative regulation of DNA-templated transcription	1
transition metal ion binding	1
histone H3 reader activity	1
nucleic acid binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

1050 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZMYND11	EMSY	Q7Z589	890
ZMYND11	DEAF1	O75398	885
ZMYND11	TAB1	Q15750	741
ZMYND11	SETD2	Q9BYW2	705
ZMYND11	TRAF3	Q13114	699
ZMYND11	H3-3A	P06351	629
ZMYND11	EFTUD2	Q15029	628
ZMYND11	CBX1	P23197	602
ZMYND11	DIP2C	Q9Y2E4	595
ZMYND11	RUNX1T1	Q06455	593
ZMYND11	ZHX1	Q9UKY1	577
ZMYND11	BMPR1A	P36894	528
ZMYND11	TRADD	Q15628	525
ZMYND11	NCOR1	O75376	490
ZMYND11	H3C1	P02295	486

IntAct

54 interactions, top by confidence:

A	B	Type	Score
DYNLL1	BLTP3B	psi-mi:“MI:0914”(association)	0.730
ZMYND11		psi-mi:“MI:0915”(physical association)	0.660
	ZMYND11	psi-mi:“MI:0915”(physical association)	0.660
LMP1	ZMYND11	psi-mi:“MI:0403”(colocalization)	0.620
LMP1	ZMYND11	psi-mi:“MI:0915”(physical association)	0.620
ZMYND11	LMP1	psi-mi:“MI:0915”(physical association)	0.620
ZMYND11	ZHX1	psi-mi:“MI:0407”(direct interaction)	0.590
ZHX1	ZMYND11	psi-mi:“MI:0915”(physical association)	0.590
ZMYND11	EBNA2	psi-mi:“MI:0915”(physical association)	0.520
LTBR	ZMYND11	psi-mi:“MI:0915”(physical association)	0.510
ZMYND11	LTBR	psi-mi:“MI:0915”(physical association)	0.510
ZMYND11	ARHGEF18	psi-mi:“MI:0407”(direct interaction)	0.440
ZMYND11	SP140	psi-mi:“MI:0407”(direct interaction)	0.440
ZMYND11	PPRC1	psi-mi:“MI:0407”(direct interaction)	0.440
ZMYND11	CRYBG3	psi-mi:“MI:0407”(direct interaction)	0.440
ZMYND11	HOMEZ	psi-mi:“MI:0407”(direct interaction)	0.440
ZMYND11	ZBTB38	psi-mi:“MI:0407”(direct interaction)	0.440
ZMYND11	PPP1R35	psi-mi:“MI:0407”(direct interaction)	0.440
ZMYND11	SLC5A7	psi-mi:“MI:0407”(direct interaction)	0.440
ZMYND11	SETBP1	psi-mi:“MI:0407”(direct interaction)	0.440
ABCC6	ZMYND11	psi-mi:“MI:0407”(direct interaction)	0.440
MLC1	ZMYND11	psi-mi:“MI:0407”(direct interaction)	0.440
TTN	ZMYND11	psi-mi:“MI:0407”(direct interaction)	0.440
CREBBP	ZMYND11	psi-mi:“MI:0407”(direct interaction)	0.440
CDT1	ZMYND11	psi-mi:“MI:0407”(direct interaction)	0.440

BioGRID (160): HIST3H3 (Protein-peptide), HIST3H3 (Reconstituted Complex), HIST3H3 (Affinity Capture-Western), HIST3H3 (Protein-peptide), HIST3H3 (Reconstituted Complex), PRPF8 (Affinity Capture-MS), SRRM2 (Affinity Capture-MS), SNRNP200 (Affinity Capture-MS), SRRM1 (Affinity Capture-MS), PNN (Affinity Capture-MS), SRSF4 (Affinity Capture-MS), SRSF1 (Affinity Capture-MS), PABPC1 (Affinity Capture-MS), EFTUD2 (Affinity Capture-MS), SAP18 (Affinity Capture-MS)

ESM2 similar proteins: A0JMY5, A2YEZ6, A3BDI8, A6QLA0, A9YUB1, B1AY10, D4A4T9, E0X9N4, O74853, P40798, P47226, P53971, Q09YN8, Q0D5B9, Q108U9, Q12986, Q15326, Q17QE2, Q18034, Q29RL2, Q2IBC3, Q2LAP6, Q2QLA1, Q2QLG8, Q4R7U2, Q54BK0, Q5PXT2, Q5R966, Q5RD91, Q5U2P3, Q5ZA07, Q5ZML4, Q67YE6, Q6DIR5, Q6IDS6, Q6NUA0, Q6ZNB6, Q7ZXE9, Q8N6M9, Q8R5C8

Diamond homologs: A2A8L1, D3ZD32, G5EBZ4, O97159, Q12873, Q14839, Q15326, Q22516, Q6PDQ2, Q8R5C8, Q8TDI0, Q9ULU4, A0A7U2QYM2, B2KF05, B2RRD7, F1R5H6, F4IXE7, F4JYC8, F4KBP5, O15164, O16102, O43918, O60885, O88491, O96028, P21675, P55201, Q03330, Q08D75, Q12830, Q15059, Q56R14, Q60544, Q64127, Q6BGW1, Q6CXW4, Q6FTW5, Q6ZPK0, Q756G9, Q7KRS9

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
ZHX1	“down-regulates activity”	ZMYND11	binding
EMSY	“up-regulates activity”	ZMYND11	binding
ZMYND11	“up-regulates activity”	H3-3A	binding
ZMYND11	“up-regulates activity”	“Histone H3”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 41 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Infectious disease	6	5.5×	8e-03

GO biological processes:

GO term	Partners	Fold	FDR
tumor necrosis factor-mediated signaling pathway	5	45.9×	3e-05
obsolete positive regulation of NF-kappaB transcription factor activity	5	28.5×	9e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

343 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	41
Likely pathogenic	27
Uncertain significance	136
Likely benign	80
Benign	25

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1064579	NM_001370100.5(ZMYND11):c.1687-1G>A	Pathogenic
1064584	NM_001370100.5(ZMYND11):c.1129del (p.Ser377fs)	Pathogenic
1064646	NM_001370100.5(ZMYND11):c.709C>T (p.Gln237Ter)	Pathogenic
1072373	NM_001370100.5(ZMYND11):c.1792del (p.Cys598fs)	Pathogenic
1209429	NM_001370100.5(ZMYND11):c.744_745del (p.Cys249fs)	Pathogenic
1335032	NM_001370100.5(ZMYND11):c.1769G>A (p.Trp590Ter)	Pathogenic
157551	NM_001370100.5(ZMYND11):c.206dup (p.Thr70fs)	Pathogenic
157552	NM_001370100.5(ZMYND11):c.976C>T (p.Gln326Ter)	Pathogenic
157554	NM_001370100.5(ZMYND11):c.561del (p.Met187fs)	Pathogenic
1704321	NM_001370100.5(ZMYND11):c.630C>G (p.Tyr210Ter)	Pathogenic
1704322	NM_001370100.5(ZMYND11):c.1089G>A (p.Trp363Ter)	Pathogenic
1704324	NM_001370100.5(ZMYND11):c.1756C>T (p.Gln586Ter)	Pathogenic
1808675	GRCh37/hg19 10p15.3(chr10:100027-291134)x1	Pathogenic
2024400	NM_001370100.5(ZMYND11):c.774C>G (p.Cys258Trp)	Pathogenic
2025242	NM_001370100.5(ZMYND11):c.1080del (p.Arg361fs)	Pathogenic
2425623	NC_000010.10:g.(?267115)(298410_?)del	Pathogenic
253634	GRCh37/hg19 10p15.3(chr10:136361-274777)x1	Pathogenic
2663152	NM_001370100.5(ZMYND11):c.705_708del (p.Glu236fs)	Pathogenic
2862741	NM_001370100.5(ZMYND11):c.872_873insA (p.Phe291fs)	Pathogenic
3244984	NC_000010.10:g.(?282758)(286930_?)del	Pathogenic
3334833	NM_001370100.5(ZMYND11):c.858_883dup (p.Pro295delinsLeuLysTer)	Pathogenic
3340629	NM_001370100.5(ZMYND11):c.946C>T (p.Gln316Ter)	Pathogenic
3660977	NM_001370100.5(ZMYND11):c.1024_1045dup (p.Glu349delinsGlyLeuGluLysGlyLeuTer)	Pathogenic
3678256	NM_001370100.5(ZMYND11):c.948del (p.Arg317fs)	Pathogenic
3725487	NM_001370100.5(ZMYND11):c.446dup (p.Lys150fs)	Pathogenic
373104	NM_001370100.5(ZMYND11):c.464_467del (p.Lys155fs)	Pathogenic
3773685	NM_001370100.5(ZMYND11):c.121_122del (p.Met41fs)	Pathogenic
3897871	NM_001370100.5(ZMYND11):c.127C>T (p.Arg43Ter)	Pathogenic
3898610	NM_001370100.5(ZMYND11):c.1206_1207del (p.Ser403fs)	Pathogenic
393552	NM_001370100.5(ZMYND11):c.22C>T (p.Arg8Ter)	Pathogenic

SpliceAI

3160 predictions. Top by Δscore:

Variant	Effect	Δscore
10:179973:T:G	acceptor_gain	1.0000
10:179979:T:TA	acceptor_gain	1.0000
10:179984:A:AG	acceptor_gain	1.0000
10:179985:T:G	acceptor_gain	1.0000
10:179987:A:AG	acceptor_gain	1.0000
10:179987:ACT:A	acceptor_gain	1.0000
10:179988:C:G	acceptor_gain	1.0000
10:179989:T:A	acceptor_gain	1.0000
10:179992:A:AG	acceptor_gain	1.0000
10:179992:AGCTA:A	acceptor_loss	1.0000
10:179993:G:GT	acceptor_gain	1.0000
10:179993:GC:G	acceptor_gain	1.0000
10:179993:GCT:G	acceptor_gain	1.0000
10:179993:GCTA:G	acceptor_gain	1.0000
10:179993:GCTAA:G	acceptor_gain	1.0000
10:180124:ACAAA:A	donor_gain	1.0000
10:180125:CAAA:C	donor_gain	1.0000
10:180126:AAA:A	donor_gain	1.0000
10:180126:AAAG:A	donor_loss	1.0000
10:180127:AA:A	donor_gain	1.0000
10:180128:AG:A	donor_loss	1.0000
10:180129:G:GG	donor_gain	1.0000
10:180129:G:T	donor_loss	1.0000
10:209884:TTCA:T	acceptor_loss	1.0000
10:209885:TCA:T	acceptor_loss	1.0000
10:209886:CAGGT:C	acceptor_loss	1.0000
10:209887:A:C	acceptor_loss	1.0000
10:209888:G:GA	acceptor_loss	1.0000
10:209888:GGT:G	acceptor_gain	1.0000
10:209888:GGTAT:G	acceptor_gain	1.0000

AlphaMissense

3243 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:209900:G:C	R43P	1.000
10:209939:T:C	L56P	1.000
10:209947:G:C	A59P	1.000
10:209948:C:A	A59D	1.000
10:209956:G:C	D62H	1.000
10:209957:A:T	D62V	1.000
10:209963:T:C	L64P	1.000
10:209986:G:C	G72R	1.000
10:209987:G:A	G72D	1.000
10:209992:A:C	K74Q	1.000
10:209992:A:G	K74E	1.000
10:209993:A:T	K74I	1.000
10:209994:A:C	K74N	1.000
10:209994:A:T	K74N	1.000
10:209995:G:A	G75S	1.000
10:209995:G:C	G75R	1.000
10:209995:G:T	G75C	1.000
10:209996:G:A	G75D	1.000
10:209996:G:T	G75V	1.000
10:210007:G:C	G79R	1.000
10:210007:G:T	G79C	1.000
10:210008:G:A	G79D	1.000
10:210017:A:C	Q82P	1.000
10:210018:A:C	Q82H	1.000
10:210018:A:T	Q82H	1.000
10:210022:G:A	G84R	1.000
10:210022:G:C	G84R	1.000
10:210023:G:A	G84E	1.000
10:210025:T:G	Y85D	1.000
10:236884:T:C	L162P	1.000

dbSNP variants (sampled 300 via entrez): RS1000026521 (10:246693 A>G), RS1000030187 (10:201542 C>T), RS1000057501 (10:148629 A>G,T), RS1000062100 (10:216612 A>C), RS1000083422 (10:201916 T>G), RS1000156787 (10:209183 T>C), RS1000185577 (10:244571 T>G), RS1000194683 (10:213459 G>A), RS1000203416 (10:143013 T>C), RS1000226655 (10:181931 A>G), RS1000238340 (10:225224 T>G), RS1000287818 (10:193431 G>A), RS1000340667 (10:129832 G>A,C), RS1000371077 (10:195509 C>T), RS1000397371 (10:187681 C>G,T)

Disease associations

OMIM: gene MIM:608668 | disease phenotypes: MIM:616083, MIM:181500, MIM:156200, MIM:614165

GenCC curated gene-disease

Disease	Classification	Inheritance
intellectual disability, autosomal dominant 30	Strong	Autosomal dominant
autosomal dominant non-syndromic intellectual disability	Supportive	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
syndromic complex neurodevelopmental disorder	Definitive	AD

Mondo (7): intellectual disability, autosomal dominant 30 (MONDO:0014486), neurodevelopmental disorder (MONDO:0700092), schizophrenia (MONDO:0005090), intellectual disability, autosomal dominant 1 (MONDO:0007974), pheochromocytoma/paraganglioma syndrome 5 (MONDO:0013602), intellectual disability (MONDO:0001071), autosomal dominant non-syndromic intellectual disability (MONDO:0015802)

Orphanet (7): Intellectual disability-expressive aphasia-facial dysmorphism syndrome (Orphanet:436151), 2q23.1 microdeletion syndrome (Orphanet:228402), Hereditary pheochromocytoma-paraganglioma (Orphanet:29072), ZMYND11-related developmental delay-speech delay-seizures-behavioral abnormalities-craniofacial dysmorphism syndrome (Orphanet:694304), ZMYND11-related developmental delay-speech delay-seizures-behavioral abnormalities-craniofacial dysmorphism syndrome due to a point mutation (Orphanet:694308), NON RARE IN EUROPE: Schizophrenia (Orphanet:3140), NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

18 total (19 of 18 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000154	Wide mouth
HP:0000248	Brachycephaly
HP:0000316	Hypertelorism
HP:0000396	Overfolded helix
HP:0000508	Ptosis
HP:0000582	Upslanted palpebral fissure
HP:0000664	Synophrys
HP:0000718	Aggressive behavior
HP:0000750	Delayed speech and language development
HP:0001252	Hypotonia
HP:0001256	Mild intellectual disability
HP:0001263	Global developmental delay
HP:0001270	Motor delay
HP:0002069	Bilateral tonic-clonic seizure
HP:0002558	Supernumerary nipple
HP:0003593	Infantile onset
HP:0012760	Reduced social responsiveness
HP:0100753	Schizophrenia

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST010725_32	Malaria	2.000000e-07
GCST010725_99	Malaria	8.000000e-08

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D065886	Neurodevelopmental Disorders	F03.625
C566947	Mental Retardation, Autosomal Dominant 1 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4739854 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — Non-enzymatic BRD containing proteins

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases methylation, affects cotreatment, decreases expression, affects expression	8
trichostatin A	affects cotreatment, decreases expression, affects expression	4
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
bisphenol F	affects cotreatment, increases expression	1
TAK-243	decreases sumoylation	1
TL8-506	affects cotreatment, increases expression	1
geldanamycin	increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	increases expression	1
geraniol	increases expression	1
beta-lapachone	decreases expression, increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
methacrylaldehyde	affects cotreatment, increases oxidation	1
CGP 52608	affects binding, increases reaction	1
entinostat	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ICG 001	increases expression	1
dorsomorphin	decreases expression, affects cotreatment	1
7-(benzylamino)-1,3,4,8-tetrahydropyrrolo(4,3,2-de)quinolin-8(1H)-one	decreases expression	1
Bortezomib	decreases expression	1
Acrolein	affects cotreatment, increases oxidation	1
Vehicle Emissions	increases abundance, increases expression	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Dexamethasone	affects cotreatment, increases expression	1
Indomethacin	affects cotreatment, increases expression	1
Methotrexate	increases expression	1
Ozone	increases oxidation, affects cotreatment	1
Poly I-C	affects cotreatment, increases expression	1
Silicon Dioxide	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4736941	Binding	Binding affinity to ZMYND11 PWWP1 domain (unknown origin) assessed as aggregation temperature at 400 uM by heating at 25 to 85 degC by differential static light scattering method	Discovery of Small-Molecule Antagonists of the PWWP Domain of NSD2. — J Med Chem

Cellosaurus cell lines

5 cell lines: 3 embryonic stem cell, 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A8E4	SEES3-1V human ZMYND11, clone1	Embryonic stem cell	Male
CVCL_A8E5	SEES3-1V human ZMYND11, clone2	Embryonic stem cell	Male
CVCL_A8E6	SEES3-1V human ZMYND11, clone3	Embryonic stem cell	Male
CVCL_TZ30	HAP1 ZMYND11 (-) 1	Cancer cell line	Male
CVCL_TZ31	HAP1 ZMYND11 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia